Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach.

ABSTRACT: Background/Objectives: Escitalopram, a first-line antidepressant, is primarily metabolized by CYP2C19. Its pharmacokinetics are altered during pregnancy. This study aims to predict maternal and fetal exposure to escitalopram during pregnancy and to propose safe and effective dosing strategies using physiologically based pharmacokinetic (PBPK) modeling. Methods: Predictive PBPK models for escitalopram were developed in nonpregnant women, pregnant women, and the fetoplacental unit using the Simcyp^® simulator. Additional models incorporating CYP2C19 phenotypes were constructed. Model performance was evaluated using visual predictive checks and by comparing predicted-to-observed ratios for the maximum plasma concentration (C_max) and the area under the curve

SUBMITTER: Choi SY 

PROVIDER: S-EPMC12567279 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature